User Agreement

Important Information – Please Read

By accessing and using this document, you are agreeing to the following terms and conditions and all applicable laws.

These documents provide information on the results of certain drug studies initiated on or after October 15, 2002 sponsored or conducted by URL Pharma or its subsidiaries or affiliates. The nature and purpose of this document is to comply with certain applicable laws and is non-promotional.

Product information provided in these documents may differ with other published data due to the limited scope of the information published here. In case of doubt, please refer to the prescribing information approved by the FDA.

No Medical Advice Included

Patients: Nothing in these documents should be construed as the giving of medical advice or the making of a recommendation. These documents should not be relied on as the basis for any decision or action or replace medical advice, medical visits or recommendations from health care providers. Any questions regarding the information in these documents should be directed to your physician.

Healthcare Providers: This is not a prescription consultation service. The information in these documents is not prescribing information, and prescribing decisions should always refer to the specific labeling information approved by the FDA.

No Representation or Warranty, No Liability

While URL Pharma uses reasonable efforts to provide accurate information in these documents, everything in these documents is provided “AS IS”. URL Pharma does not make, and expressly disclaims, any representations or warranties of any kind, either express or implied (including without limitation any implied warranties of merchantability, fitness for a particular purpose or non-infringement) with regard to any such information, its accuracy or completeness or the frequency that it is updated. URL Pharma assumes no liability or responsibility for any errors or omissions in the content of these documents and your use of this document is at your own risk. URL Pharma (including its officers, directors, employees or affiliates) shall not be liable for any damages of any kind or any claims or losses, resulting from or in connection with the creation or use of, or reliance on, this document.

Impermissible Use

These documents do not confer rights in any trademarks and service marks used in these documents, whether owned by URL Pharma or others. The results data provided in these documents are the property of URL Pharma and may not be copied, transcribed, published or otherwise used, without written permission.

Applicable Law

These terms and conditions shall be governed by and construed in accordance with the laws of the State of Pennsylvania, without regard to its choice of law principles

History

Overview

History

People

Mission / Strategy

Careers

In 1946, United Research Laboratories (URL) was founded by Albert Roberts, a bench chemist with a degree from the University of Pittsburgh. Initially, the company manufactured and sold ACTH directly to physicians to treat arthritis. From this, the Company developed a significant pharmaceutical distribution business which sustained the Company for the ensuing 40 years.

In 1986, seeing that their manufacturers were starting to bypass distributors like URL, Mr. Roberts and his brother, Theodore Roberts, Ph.D., established Mutual Pharmaceutical Company to develop and manufacture generic pharmaceutical products.

In 1988, Albert Roberts' son, Richard H. Roberts, M.D., Ph.D., left the Brigham and Women’s Hospital, of Harvard Medical School, to join the Company. Dr. Richard Roberts became the Chief Operating Officer in 1989, assuming control of the operations and leading the company to profitability.

In 1997, venture capital investors (Elliott Associates and Momar Corporation) purchased a majority of the company. Dr. Richard Roberts, the only remaining member of the founding Roberts family, maintained a minority interest and became President, CEO and Chairman of the Board.

In 2001, net sales exceeded $100 million dollars, the research & development budget rose to $12 million and annual production reached 2 billion tablets and capsules. URL was then manufacturing 35 products, had 14 ANDAs pending FDA approval, and distributed third-party tablets, capsules, liquids, creams, ointments, and injectables.

In 2004, foreseeing that the profitability of the generic pharmaceutical marketplace would deteriorate over the next 5 years as Asian manufacturers gained FDA approvals of generic drugs, the Company embarked upon an aggressive and challenging plan to transform into a medically and scientifically focused branded and technology business. As part of this effort, R&D spending was greatly expanded and the R&D focus transitioned away from commodity generic products towards first-to-file patent challenge generics, branded product development, and technology development. The Company also established AR Scientific to be the Company's branded marketing division. AR Scientific currently markets two NDA products, Qualaquin® and Bactrim™. The Company also launched felodipine ER, a technically challenging product, and remained the exclusive generic for over 3.5 years.

In 2005, the Company had annual sales of over $300 million and signed a licensing deal with King Pharmaceutical which granted King certain rights to the Company’s technology and paid the Company $35 million plus an on-going royalty.

In 2006, the Company launched Qualaquin® (quinine sulfate), the Company’s first internally developed branded product and the only FDA approved version of quinine sulfate. Qualaquin® has Orphan Drug exclusivity until August, 2012.

In 2007, the Company had annual sales of $483MM, over 250 approved ANDAs, 4 approved NDAs, licensing deals, multiple high barrier ANDAs, and a broad portfolio of proprietary products under development.

In 2008, the Company is poised for unprecedented growth. The Company changed its name to URL Pharma, passed 2 pivotal studies for separate new drugs and is preparing the corresponding New Drug Applications with FDA. URL Pharma has developed multiple pharmaceutical technologies such as PRISM™,NanoBurst™,MultiBurst™ and Z-Burst™, and continues to progress the development of its proprietary pipeline.

Click here to see a visual timeline.